Daptomycin (formerly LY146032) is a new antimicrobial agent most appropriately described as a cyclic peptide with a lipophilic decanoyl tail or side chain (6, 8) . This compound has a significant activity against gram-positive pathogens, including Staphylococcus spp., s.treptococci, Enterococcus spp., Listeria monocytogenes, and clinically important anaerobic bacteria such as Clostridium difficile (2, 4, 5, 7) .
Effects of Reduced Cation Supplement Recommendations (National Committee for Clinical Laboratory Standards) on Daptomycin Antistaphylococcal Activity
Daptomycin (formerly LY146032) is a new antimicrobial agent most appropriately described as a cyclic peptide with a lipophilic decanoyl tail or side chain (6, 8) . This compound has a significant activity against gram-positive pathogens, including Staphylococcus spp., s.treptococci, Enterococcus spp., Listeria monocytogenes, and clinically important anaerobic bacteria such as Clostridium difficile (2, 4, 5, 7) .
Several authors have demonstrated a remarkable calcium ion-dependent daptomycin potency (2, 4, 5, 7) . In many of these experiments limited numbers of strains were tested and/or the cationic concentrations were not relevant to current standardized broth susceptibility testing procedures (10).
The National Committee for Clinical Laboratory Standards (NCCLS) recently altered their recommendations for Mueller-Hinton broth.(MHB) divalent cation content principally based on the aminoglycoside studies reported by Barry et al. (3) . Those studies did not address other ion-dependent antimicrobial susceptibility test results, e.g., with bacitracin, lipophilic polypeptides, polymyxins, and tetracyclines.
Since daptomycin has a calcium-dependent bacterial membrane interaction that promotes a possible cytoplasm-based peptidoglycan synthesis alteration (1, 8) , it seems prudent to consider the effects of the recent NCCLS supplement recommendations on daptomycin broth MICs. In this letter I report the results of testing 587 staphylococcal strains in two types of cation-adjusted MHB. media (9, 10). The broth microdilution trays were prepared by incorporating twofold dilu.tions of daptomycin (Eli Lilly Research Laboratories, Indianapolis, Ind.) into MHB (Difco Laboratories, Detroit, Mich.) having final divalent cation concentrations of (i) 50 mg of calcium and 25 mg of magnesium per liter (9) and (ii) 20 mg of calcium and 10 mg of magnesium per liter (10). The organisms tested included oxacillin-susceptible Staphylococcus aureus (148 strains), oxacillin-resistant S. aureus (275 strains), oxacillin-susceptible coagulase-negative Staphylococcus spp. (45 strains), and oxacillin-resistant coagulase-negative Staphylococcus spp. (119 strains). AU coagulase-negative staphylococci (10 species) were recently isolated from clinical bacteremias, and the S. aureus strains came from blood and nosocomial wound infection cultures at 42 U.S. medical centers. Results with all species were very similar, and the data were merged for presentation. Oxacillin resistance (MIC, >2 ,ug/ml) was determined in 2% NAClsupplemented MHB and confirmed by methicillin MICs and 1-,ug oxacillin disk test results (9, 10). Table 1 summarizes the daptomycin MIC results obtained with two levels of divalent cation supplementation (9, 10). As predicted from earlier experiments (2, 4, 5, 7), daptomycin was more active at the previously recommended higher calcium supplement concentration (9). Using the commonly reported M1C50 and MIC%0 (MICs for 50 and 90% of strains tested, respectively) statistics, only the daptomycin MIC%0 result was elevated from 0.5 to 1.0 ,ug/ml by lowering the calcium supplement level (10). In both media, daptomycin MICs were all s2.0 ,uglml, i.e., the susceptibility breakpoint MIC tentatively recommended in our earlier publication (7) .
A more sensitive statistical or reporting method to recognize the calcium effect on daptomycin activity was proposed by Calcium ( Our results showed a slight reduction (less than twofold) in daptomycin potency that would not significantly compromise the drug's apparent spectrum of activity against contemporary staphylococcal isolates ( 
